

US Distribution Agreement Signed with Luminary Health

- A distribution agreement has been signed with Luminary Health Centers to deliver a consumer microbiome test in the United States
- The initial 12 month phase of the agreement has a value of USD \$458,000 to Microba
- Luminary is an established wellness group which delivers genomic-driven health services across the US from clinics in California
- The partnership will deepen access to Microba's testing technology in the United States

Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that a distribution agreement has been executed with Luminary Health Centers Inc. to distribute a microbiome test powered by Microba's testing technology to consumers in the United States.

Luminary is an established wellness group which delivers genomic driven health services to individuals across the US from clinics based in California. The agreement signed with Luminary provides non-exclusive distribution rights out to 2027 to deliver a Microba powered test to consumers in the United States. The initial 12 month phase of the agreement has a value of USD \$458,000 to Microba, with subsequent stages which could provide for potential greater financial commitments subject to agreement between the parties.

This partnership continues to expand Microba's distribution base to deliver Microba's testing technology to clinicians, patients and consumers.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About Luminary Health Centers Inc

Luminary Health Centers is an established wellness group with an approach to optimize health at a cellular level and prioritize preventive health practices to overcome chronic diseases and live a high quality of life.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.